S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
NASDAQ:NERV

Minerva Neurosciences - NERV Stock Forecast, Price & News

$2.92
-0.07 (-2.34%)
(As of 12/7/2022 10:39 AM ET)
Add
Compare
Today's Range
$2.92
$3.13
50-Day Range
$2.55
$13.43
52-Week Range
$2.51
$15.27
Volume
442 shs
Average Volume
233,700 shs
Market Capitalization
$15.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
174.0% Upside
$8.00 Price Target
Short Interest
Bearish
5.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.10) to ($3.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

803rd out of 1,023 stocks

Pharmaceutical Preparations Industry

396th out of 501 stocks

NERV stock logo

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Stock News Headlines

See More Headlines
Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Company Calendar

Last Earnings
11/08/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NERV
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+174.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-49,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$41.18 million
Book Value
$1.49 per share

Miscellaneous

Free Float
5,046,000
Market Cap
$15.59 million
Optionable
Optionable
Beta
-0.27

Key Executives

  • Dr. Remy Luthringer Ph.D. (Age 61)
    Exec. Chairman & CEO
    Comp: $1.19M
  • Mr. Geoffrey Robin Race F.C.M.A. (Age 61)
    FCMA, M.B.A., MBA, Pres
    Comp: $880.44k
  • Mr. Frederick W. Ahlholm CPA (Age 56)
    CPA, Sr. VP, CFO & Sec.
    Comp: $610.68k
  • Prof. Michael Davidson M.D. (Age 72)
    Chief Medical Officer
    Comp: $657.47k
  • Mr. Joseph Reilly (Age 47)
    Sr. VP & COO
  • Mr. William B. Boni (Age 70)
    VP of Investor Relations & Corp. Communications
  • Dr. Ramana Kuchibhatla Ph.D.
    Sr. VP and Head of R&D













NERV Stock - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares.
View NERV analyst ratings
or view top-rated stocks.

What is Minerva Neurosciences' stock price forecast for 2023?

2 brokerages have issued 1 year price targets for Minerva Neurosciences' stock. Their NERV share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 167.6% from the stock's current price.
View analysts price targets for NERV
or view top-rated stocks among Wall Street analysts.

How have NERV shares performed in 2022?

Minerva Neurosciences' stock was trading at $6.4080 at the beginning of the year. Since then, NERV shares have decreased by 53.3% and is now trading at $2.99.
View the best growth stocks for 2022 here
.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 249,200 shares, an increase of 79.3% from the October 31st total of 139,000 shares. Based on an average daily volume of 3,610,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 5.5% of the company's shares are sold short.
View Minerva Neurosciences' Short Interest
.

When is Minerva Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our NERV earnings forecast
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($1.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.76). During the same period last year, the firm posted ($1.52) EPS.

When did Minerva Neurosciences' stock split?

Minerva Neurosciences shares reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.06%), Renaissance Technologies LLC (1.91%), BlackRock Inc. (1.46%), Group One Trading L.P. (0.00%), Point72 Asset Management L.P. (0.47%) and Truist Financial Corp (0.21%). Insiders that own company stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer.
View institutional ownership trends
.

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $2.99.

How much money does Minerva Neurosciences make?

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $15.97 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($8.76) on an earnings per share basis.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 12/7/2022 by MarketBeat.com Staff